MOLECULAR partners

Extending the Boundaries of Targeted Cancer Therapies



Full-Year 2025 Financials

Patrick Amstutz, CEO

March 12, 2026

Disclaimer

This presentation contains forward looking statements. Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including without limitation: implied and express statements regarding the clinical development of Molecular Partners' current or future product candidates; expectations regarding timing for reporting data from ongoing clinical trials or the initiation of future clinical trials; the potential therapeutic and clinical benefits of Molecular Partners' product candidates and its RDT and Switch-DARPin platforms; the selection and development of future programs; Molecular Partners' collaboration with Orano Med including the benefits and results that may be achieved through the collaboration; the expected benefits of Molecular Partners' SAB and new CSO; the expected benefits of the strategic review; and Molecular Partners' expected business and financial outlook, including anticipated expenses and cash utilization for 2026 and its expectation of its current cash runway. These statements may be identified by words such as "aim", "anticipate", "expect", "guidance", "intend", "outlook", "plan", "potential", "will" and similar expressions, and are based on Molecular Partners' current beliefs and expectations. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Some of the key factors that could cause actual results to differ from Molecular Partners' expectations include, but are not limited to, those set forth in under the heading "Risk Factors" in Molecular Partners' Annual Report on Form 20-F for the year ended December 31, 2025 and other filings Molecular Partners makes with the SEC from time to time. These documents are available on the Investors page of Molecular Partners' website at www.molecularpartners.com. In addition, this presentation contains information relating to interim data as of the relevant data cutoff date, results of which may differ from topline results that may be obtained in the future.

Any forward-looking statements speak only as of the date of this presentation and are based on information available to Molecular Partners as of the date of this release, and Molecular Partners assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise..

Extending the Boundaries of Targeted Cancer Therapies

DARPin
Designed Ankyrin Repeat Protein



Our Company

- Clinical-stage biotech company, founded 2004
- Operations & listing in Switzerland (SIX, 2014) and US (Nasdaq, 2021)
- Financed (USD ~116 M / CHF ~93 M*) to capture upcoming value inflection points

Our Capabilities

- **DARPin therapeutics**: novel class of drugs, clinically-validated, proprietary platforms
- Strong team to innovate and execute up to clinical POC
- Partnerships with world-class experts to maximize patient value

Our Pipeline

- Differentiated **Assets** with focus in **Oncology**
- **MP0712 / Targeted radiotherapy** and **next-gen immune cell engagers**
- Early clinical readouts for patient value across indications with high unmet need

*Financials as of December 31, 2025.
POC, proof of concept.

Continued Innovation in DARPin Discovery, Therapeutic Designs

DARPin Drug Design Process

Proprietary DARPin Libraries

- Powered by >20 years of clinical learnings
- Designed for low immunogenicity



Differentiated Candidates

Radio-DARPin therapeutics



Conditional, logic-gated Switch-DARPin candidates



Multispecific DARPin candidates

Tailored to Patient Needs



Targeted DARPin Therapeutics

- ✓ Highly precise tumor targeting
- ✓ Tumor-localized activity
- ✓ Low uptake in healthy tissues

Our Pipeline – Differentiated Therapeutics for Patient Value

PLATFORM	CANDIDATE	RESEARCH	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
Radio-DARPin Therapy (RDT)	**MP0712**	**SCLC & NECs** *^{212}Pb x DLL3*		oranomed *Co-development**		
	MP0726	**Ovarian Cancer** *^{212}Pb x MSLN*	oranomed *Co-development**			
	Undisclosed Programs (Solid Tumors)	**Radio - C**				
		Radio - D				
		Radio - E				
		Radio - F				
Next-Gen Immune Cell Engagers	MP0317	**Advanced Solid Tumors** *FAP x CD40*				
	MP0533	**r/r AML and AML/MDS** *CD33 x CD123 x CD70 x CD3*				
	Switch-DARPin T Cell Engager	*CD3 x CD2 x MSLN x EpCAM*				
	MP0621 (Switch-DARPin)	**HSCT** *cKit x CD16a x CD47*				

*The co-development agreement with Orano Med includes up to 10 targeted radiotherapy programs, including MP0712 and MP0726.
AML, acute myeloid leukemia; DLL3, Delta-like ligand 3; EpCAM, epithelial cell adhesion molecule; FAP, fibroblast activation protein; MDS, myelodysplastic syndrome; MSLN, mesothelin; NEC, neuroendocrine cancer; r/r, relapsed/refractory; SCLC, small cell lung cancer.

Corporate Highlights 2025

MP0712	• **Initiated US Phase 1/2a study of MP0712, ^{212}Pb-based DLL3-targeting Radio-DARPin candidate**, co-developed with Orano Med, for SCLC and other neuroendocrine cancers • **Precise targeting of tumor lesions in patients** shown with ^{203}Pb-labeled MP0712 (TWC 2026)
Radio-DARPin Therapy (RDT)	• Nominated lead candidate MP0726 targeting MSLN, pre-clinical data presented at SNMMI 2025 • Development agreement signed with Eckert & Ziegler enabling RDTs with ^{225}Ac • Formed Scientific Advisory Board, chaired by nuclear medicine expert Prof. Ken Herrmann
MP0317	• Started Phase 2 randomized IIT of tumor-localized CD40 agonist MP0317 for cholangiocarcinoma
MP0533	• Mutation-agnostic clinical benefit of novel TCE MP0533 for AML presented at ASH 2025
Switch-DARPin	• Pre-clinical logic-gated T cell activation through Switch-DARPin presented at AACR and SITC 2025
Operations	• **Strong financial position** with CHF 93.1 M in cash as of December 31, 2025 • Completed strategic review of operations and organization, extending runway into 2028 • Appointed Martin Steegmaier, PhD, as CSO and member of Executive Committee

*Financials as per December 31, 2025.
FIH, first in human; TWC, Theranostics World Congress.



Financial overview & Team update

FY 2025 Financial Highlights

- Strong financial position with CHF 93 million in cash (incl. short term deposits) as of December 31, 2025
- Net cash used in operating activities of CHF 51.3 million in 2025
- Operating loss of CHF 58.1 million in 2025, including a charge of CHF 2.6 million related to the June 2025 restructuring
- Company expects to be funded until 2028, excluding any potential payments from R&D partnerships

Key Figures 2025

(CHF million, except per share and FTE data)	*FY 2025*	*FY 2024*	*Change*
Revenues	**-**	**5.0**	**(5.0)**
Total operating expenses	**(58.1)**	**(66.2)**	**8.1**
Operating result	**(58.1)**	**(61.2)**	**3.1**
Net financial result	**(3.5)**	**7.2**	**(10.7)**
Net result	**(61.6)**	**(54.0)**	**(7.6)**
Basic net result per share (in CHF)	**(1.65)**	**(1.59)**	**(0.06)**
Net cash from / (used in) operations	**(51.3)**	**(59.2)**	**7.9**
Cash balance (incl. s.t. deposits) as of Dec 31	**93.1**	**149.4**	**(56.3)**
Number of FTE's as of Dec 31	**134.0**	**158.5**	**(24.5)**

Martin Steegmaier, PhD

- Appointed as Chief Scientific Officer (CSO) and member of the Executive Committee, effective October 1, 2025
- Deep experience in oncology drug development, including advancement of innovative cancer therapies at major biotech and pharma companies:
  - CSO at SOTIO Biotech (IO-therapies & ADCs for oncology)
  - Head of Research at MorphoSys (antibody-based therapeutics in oncology)
  - Head of Discovery for Large Molecule Research at Roche Innovation Center (Munich) (antibodies, TCEs, …)
- Ph.D. in biochemistry from the University of Basel
- MBA from the Edinburgh Business School

MOLECULAR partners

Radio-DARPins

- Ideal vectors for precise delivery of potent radio-isotopes
- Potential to unlock broad target space across solid tumor indications



Designing Radio-DARPin Therapeutics for Patients

Matching

target & disease biology
x
vector
x
isotope

to address unmet medical need



Radio-DARPins for Next-Gen Targeted Alpha Therapy

DARPin: IDEAL VECTOR FOR RADIOPHARMACEUTICALS

- Proven selective targeting
- High affinity, tumor retention
- Broad target space
- Small size



ALPHA-EMITTING THERAPEUTIC ISOTOPES

- Proven clinical efficacy
- High energy deposition
- Lead-212 (^{212}Pb)
- Actinium-225 (^{225}Ac)

SURFACE ENGINEERING

- Enabled by high stability
- Reduce kidney accumulation

HALF-LIFE EXTENDER

- Tailored systemic exposure
- Promote tumor uptake

Global Partnership to Develop ^{212}Pb Radio-DARPin Therapeutics

Combining DARPin versatility with the power of ^{212}Pb for next-gen Targeted Alpha Therapy

MOLECULAR PARTNERS
PIONEERS of DARPin THERAPEUTICS

ORANO MED
PIONEERS of TARGETED ALPHA THERAPY

FULL VALUE CHAIN PARTNERSHIP

World class technologies & capabilities combined

INDIANA, US:
Industrial scale manufacturing
Global shipping hub
ATLab US

TEXAS, US:
Preclinical development
GMP supply for early clinical phases

SWITZERLAND:
Preclinical assessment
DARPin engine, fast & high throughput

FRANCE:
^{212}Pb starting material
ATLab Europe

Pipeline of ten ^{212}Pb radiotherapy products

1	^{212}Pb x DLL3	**MP0712**
2	^{212}Pb x MSLN	**MP0726**
3		
4		
5		
6		
7		
8		
9		
10		

4 Radio-DARPin programs
50:50 cost and share split

2 MP-owned programs
with opt-in option for OM for
50:50 cost:share split

4 MP-owned programs

Our Scientific Advisory Board to Accelerate Development of Targeted Radiotherapeutics

Ken Herrmann, M.D.
Chair

James Cook
Member

Jason Lewis, Ph.D.
Member

Michael Morris, M.D.
Member

- Chaired by Prof. Ken Herrmann, M.D., globally renowned expert in the field of nuclear medicine
- Other Board members bring significant clinical and industry expertise, supporting transition from early clinical validation to strategic development

MOLECULAR partners

MP0712

Targeted Radiotherapy for Lung Cancer

- Specific tumor uptake reported in initial human images
- Phase 1/2a in US open, early data in 2026



MP0712 - Why DLL3 Targeted Radio Therapy for SCLC



Radio Therapy (MP0712)
- Phase 0/1
- SCLC highly radio sensitive
- Manageable side effects
- Combinable with other MoAs

T Cell Engagers
- Tarlatamab approved
- 40% RR
- DoR: 9.7 months
- Substantial side effects (CRS)

Antibody-Drug Conjugates
- Phase 1/2
- 50–70% RR
- DoR: 5–6 months
- Risk of chemo-resistance
- Manageable side effects

DoR, duration of response; MoA, mode of action; RR, response rate.

MP0712: Favorable Biodistribution and Potent Efficacy

In mouse models matching the low DLL3 expression levels of patients

High Tumor Accumulation

(Tumor > Kidney)



Reduction of Established Tumors



Steiner et al., TRP 2024;
Croset et al., EANM 2024;
Lizak et al., SNMMI 2024.

BioD study in NCI-H82 i.v. model. Dose: 10 µCi of ^{212}Pb at 0.01 mg/kg of DLL3 DARPin.
Efficacy study in NCI-H82 s.c. model / MP0712 and negative control injected 4x 10 µCi at 0.01 mg/kg or 8x 5 µCi at 0.01mg/kg every week; 10 µCi = 370 kBq.

MP0712: Rapid Internalization and Accumulation in Cells

Very low DLL3 copy number

DLL3: <1000 receptors/cell
PSMA: >100'000 receptors/cell



DLL3 DARPin is rapidly internalized*…



… and accumulates over time in cells**



PSMA: Lückerath et al., JNM 2018; Kwon et al, Journal of Biomedical Optics 2023. DLL3 quantification carried out in-house, on NCI-H82 tumors, n=6.
Internalization of DARPins labelled with anti-DARPin Fab-Alexa 488 conjugate into *SHP-77 human SCLC cells, into **hDLL3-HEK cells.
MFI, Mean Fluorescence Intensity; PSMA prostate-specific membrane antigen.

MP0712: High Tumor Uptake via DLL3 Replenishment and Half-Life Engineering



- DARPin
- Nucleus
- Endosome



Optimal half-life for tumor uptake of MP0712



DARPin half-life optimization allows to leverage rapid internalization & replenishment of DLL3 for high MP0712 accumulation in tumors

Immunofluorescence co-staining of anti-DARPin antibody, an early endosomal marker (EEA1) and cell nucleus marker (DAPI) after 3 h incubation. Schematic for uptake in blood and tumors with and without HLE in mice – data presented at multiple conferences in 2024.

MP0712 Development Pathway

1. Imaging



2. Treatment



Named Patient Access Program:

- Imaging and dosimetry with ^{203}Pb
- Option for treatment with ^{212}Pb

*Request from NuMeRI, Pretoria, South Africa**

Phase 1/2a Study:

- Safety of **^{212}Pb**
- Efficacy signals
- Includes an imaging and dosimetry step with ^{203}Pb

NuMeRI, Nuclear Medicine Research Infrastructure; SCLC, small cell lung cancer; SPECT, single-photon emission computed tomography.

SPECT/CT Imaging with ^{203}Pb-MP0712 in a Patient with Metastatic Small Cell Lung Cancer (mSCLC)

Patient characteristics

- 69-year-old male (smoker)
- Small cell neuroendocrine carcinoma of the lung
- Stage III at referral (mediastinal lesion)

Treatment history

- Radio- & chemotherapy

Dosing

- 185 MBq of ^{203}Pb-MP0712

Result

- Stage IV by MP0712 - SPECT with 4 liver mets



Initial high blood pool, followed by specific uptake in primary & metastatic lesions over time in line with MP0712 MoA

Patient imaged as part of a Named Patient Access Program at NuMeRI, Pretoria, South Africa.
Example of patient case series presented with courtesy of Prof. Dr. M. Sathekge.
Complete SPECT/CT imaging data set presented at TWC 2026 by Dr. Joseph Kabunda (Abstract-ID 207).

Biodistribution Profile of ^{203}Pb-MP0712 in mSCLC Patient



- **Continued tumor uptake** during imaging period (up to 116 h)
- **Higher uptake in liver metastases** as compared to primary lesion
- **Washout from healthy organs** visible from 24 h onwards
- Healthy organ profile consistent with profile observed in other patients

Lizak et al. TWC 2026.

Quantitative image analysis performed by RAPID, LLC.
mSCLC, metastatic small cell lung cancer.

Uptake of ^{203}Pb-MP0712 in Tumors of Patients with Different DLL3-Expressing Cancers



Mediastinal Lesion Metastatic Lesion

Patients imaged as part of a Named Patient Access Program at NuMeRI, Pretoria, South Africa.
Complete SPECT/CT imaging data set presented at TWC 2026 by Dr. Joseph Kabunda (Abstract-ID 207).

^{203}Pb-MP0712 Uptake in Tumor Lesions







	SUV_{mean}	SUV_{max}*
mSCLC	10.6 (Day 5)	*67*
SCLC	4.5 (Day 5)	*88*
mUC	10.3 (Day 7)	*402*

- **Progressive uptake** of MP0712 across different tumor types
  - ~80% of uptake reached at 24h
  - **Strong tumor retention** with continued uptake during imaging period (up to 7 days)
- **Preferential uptake in metastatic lesions**
  - ➢ **Ph1 study** in US expected to enroll **metastatic SCLC patients**

Complete SPECT/CT imaging data set presented at TWC 2026 by Dr. Joseph Kabunda (Abstract-ID 207).
Quantitative image analysis performed by RAPID, LLC.
* SPECT imaging with ^{203}Pb does not allow reliable SUV_{max} determination.

mUC, metastatic urothelial bladder cancer; SUV, standard uptake volume.

MP0712 Organ Dosimetry and Projection to Phase 1

^{203}Pb Time-Activity Curves



Dosimetry extrapolations suggest kidneys & red marrow as potential dose-limiting organs for ^{212}Pb-MP0712



- At Phase 1 starting dose (75 MBq) and at max. anticipated single dose (200 MBq) all healthy organs are within EBRT limits

➢ Monitor hematologic recovery to guide repeated dosing strategies

Dosimetry calculations for ^{212}Pb performed by RAPID, LLC on 5 evaluable patients; RBE = 5.
Complete dosimetry dataset presented at TWC 2026 by Dr. Kamo Ramonaheng (Abstract-ID 260).

EBRT, external beam radiation therapy; RBE, relative biologic effectiveness.

MP0712 Preclinical Safety Data Support Heme Recovery Hypothesis





- **Complete recovery of body weight loss after 10 days**
- **Complete recovery of hematologic profile after 28 days**
- **MP0712 treatment up to 30 µCi / 1.11 MBq well tolerated**

Croset A. et al. AACR 2025.

MP0712 DRF study done in WT mice
^{212}Pb-DOTAM-DARPin injected once from 10 to 60µCi.

MP0712 Phase 1/2a Study for SCLC and other NECs

- First-in-Human, US multicenter, Phase 1/2a study of MP0712 monotherapy (NCT07278479)
- Patients with small cell lung cancer (SCLC) and other neuro-endocrine cancers (NECs)
  - Every patient will be imaged (^{203}Pb) before treatment (^{212}Pb)
  - Patient pre-selection on DLL3 expression: not planned for SCLC and LC NEC of lung, foreseen for epNEC

Phase 1: Dose Escalation
Main objectives: safety, RP2D
N=15–39 patients SCLC and lung LC NEC; N=9-39 patients epNEC

Phase 2a: Dose Expansion and PoC
Main objectives: efficacy signals, confirm safety and RP2D
N=30 patients SCLC and NEC



* Evaluable patients (Bayesian Logistic Regression Model guided dose escalation)

**epNEC to start at a dose level previously tested in SCLC or LC NEC of lung at which a first signal of pharmacological activity is detected. RP2D for epNEC is anticipated to be same as RP2D for SCLC/LC NEC of lung.

1/2L, 1st/2nd line; DL, dose level; IO, immuno-oncology; LC NEC, large cell neuroendocrine cancer; PoC, proof-of-concept; RP2D, recommended phase 2 dose.

Clinical Perspective on Data Presented

Prof. Ken Herrmann, M.D.
Chair, Department of Nuclear Medicine,
University Hospital Essen, Germany
&
Chair, Scientific Advisory Board,
Molecular Partners

➢ **All boxes checked:**

- First **favorable in human biodistribution** represents an important milestone
- ^{203}Pb-MP0712 SPECT images indicate **strong tumor uptake** visible until 120-168h
- Majority of tumor lesions show increased uptake over time, whereas **normal organ uptake seems to wash out**
- Visual and dosimetric results clear the bar of first in human therapy trial with **highest intended starting dose within EBRT limits**

➢ Next: **see how the therapeutic (^{212}Pb-MP0712) performs** in patients: now clinical parameters are key

MP0712 Conclusions



Conclusion

- **Optimized tumor uptake and retention**, by leveraging DLL3 replenishment/internalization
- **Favorable biodistribution and dosimetry on healthy organs**
- **Support MP0712 Phase 1 study design** starting at meaningful dose for DLL3+ indications

Outlook

- **MP0712 Phase 1/2a study open** in the US, recruitment open
- Initial **safety data anticipated in H1** 2026, initial **activity in H2 2026**

MOLECULAR partners

MP0726

Targeted Radiotherapy for Ovarian Cancer

- Targeting membrane-bound MSLN
- Progressing to FIH imaging



^{212}Pb x MSLN Targeted Radio-DARPin for Ovarian Cancer (OC)

Combining distinctive DARPin features with the power of ^{212}Pb for next-gen targeted alpha therapy

OC: high medical need and marginal progress

- > 50% patients die within 5 years post-diagnosis (diagnosis often in late stage)
- Poor treatment options: ~80% recurrence rate post 1L chemo, limited 2L options (FRα-targeted Tx relevant for only 40% patients)

MSLN: a promising target for OC as 1st indication

- Highly expressed in OC (>80% prevalence), expression maintained in metastases
- Shed MSLN detected in serum of OC patients, might limit efficacy of MSLN-targeted therapies[1,2,3,4] (e.g., CAR T/NK, ADC, TCE in development)

RDT x MSLN: targeted delivery of alpha radiation with ^{212}Pb

- MSLN DARPin targets **membrane-proximal epitope** (and not shed MSLN)
- ^{212}Pb payload: high energy alpha emissions in short time frame
- Potential for combinations with immunotherapy (incl. next-gen TCEs)

Product composition



1. Awuah et al. 2016; 2. Zhang et al. 2011; 3. Smith et al. 2024 (ASCO poster); 4. Pastan et al. 2024.
ADC, anti-drug conjugate; CAR T, chimeric antigen receptor T cell; FRα, folate receptor alpha; MSLN, mesothelin; NK, natural killer cell; OC, ovarian cancer; TCE, T cell engager; Tx, treatment.

MP0726: ^{212}Pb x MSLN Radio-DARPin for Ovarian Cancer

Cell binding maintained despite shed MSLN



Favorable biodistribution

in hMSLN-MC38 tumor model



Outlook: Progressing MP0726 to FIH imaging

Wullschleger, et al., AACR 2025.

OVCAR-8 Cell binding competition assay (100nM DARPin with increasing concentration of shed MSLN). Mice xenografted s.c. with hMSLN-MC38 (Biocytogen). Dose: 10 µCi of ^{212}Pb at 0.01 mg/kg of MSLN DARPin. FIH, first in human.

Long tumor retention make DARPins alpha-agnostic



- DARPin profile can work for both ^{212}Pb and/or ^{225}Ac
- Opportunity to evaluate both isotopes in parallel and decide on the best isotope with data



Data on interchangeability of chelators and isotopes for Radio-DARPins
to be presented at 3rd Global Radiopharmaceuticals Development Summit in March 2026

Radio-DARPins – Isotope-Agnostic Vector play



DARPin, designed ankyrin repeat protein.

MOLECULAR partners

Concluding Remarks & Outlook

Our Radio-DARPin Pipeline – News Flow in 2026



*The co-development agreement with Orano Med includes up to 10 targeted radiotherapy programs, including MP0712 and MP0726.
DLL3, Delta-like ligand 3; MSLN, mesothelin; NEC, neuroendocrine cancer; SCLC, small cell lung cancer.

Our Pipeline – Up-Side Potential outside Radio

PLATFORM	CANDIDATE	RESEARCH	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3
Radio-DARPin Therapy (RDT)	MP0712	SCLC & NECs ^{212}Pb x DLL3				
	MP0726	Ovarian Cancer ^{212}Pb x MSLN	oranomed Co-development*			
	Undisclosed Programs (Solid Tumors)	Radio - C				
		Radio - D				
		Radio - E				
		Radio - F				
Next-Gen Immune Cell Engagers	MP0317	Advanced Solid Tumors FAP x CD40				
	MP0533	r/r AML and AML/MDS CD33 x CD123 x CD70 x CD3				
	Switch-DARPin T Cell Engager	CD3 x CD2 x MSLN x EpCAM				
	MP0621 (Switch-DARPin)	HSCT cKit x CD16a x CD47				

Additional programs with up-side potential & [minimal MP investment]

MOLECULAR partners

*The co-development agreement with Orano Med includes up to 10 targeted radiotherapy programs, including MP0712 and MP0726.
AML, acute myeloid leukemia; DLL3, Delta-like ligand 3; HSCT, hematopoietic stem cell transplant; MDS, myelodysplastic syndrome; MSLN, mesothelin; NEC, neuroendocrine cancer; r/r, relapsed/refractory; SCLC, small cell lung cancer.

Outlook and Milestones in 2026

MP0712	• **First-in-Human Phase 1 study open in US, recruitment open** • Full imaging and dosimetry data from South Africa presentation at TWC in January 2026 • Initial safety data from Phase 1 anticipated in H1 2026, initial activity in H2 2026
Radio-DARPin Therapy (RDT)	• Progress **MP0726 towards FIH imaging** • Nomination of new RDT programs mid 2026
MP0533	• Conclusion of dose escalation, update in H1 2026 • **Investigator-initiated combo trials** under discussion
Switch-DARPin	• **Lead candidate selection** in H1 2026, update at AACR 2026
MP0317	• **Phase 2 investigator-initiated combo study started** in France, now dosing patients

Cash USD ~116 M (CHF 93.1 M*, incl. short-term time deposits) ensures funding until 2028

*Financials as per December 31, 2025.
FIH, first in human; TWC, Theranostics World Congress.

MOLECULAR partners

Twenty Years of Pioneering
DARPin Therapeutics for Patients

Thank You



Our Team, Summer 2025